TRDA

Entrada Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 2/10
  • Value↓ 0/10
Entrada Therapeutics sales and earnings growth
TRDA Growth
Fair
  • Revenue Y/Y↓ -96.67%
  • EPS Y/Y↓ -592.59%
  • FCF Y/Y↓ -126.93%
Entrada Therapeutics gross and profit margin trends
TRDA Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -2895.10%
  • ROIC 5Y↓ -6.22%
Entrada Therapeutics net debt vs free cash flow
TRDA Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Entrada Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks